INGN · CIK 1294133
What Inogen, Inc. told the SEC could break it.
Inogen's disclosures cluster on a concentrated supply chain and reimbursement dependence. It sources some components, subassemblies, and even completed products from single-source or a limited group of suppliers — with three major vendors alone accounting for about 40% of raw-material purchases in 2025 — so losing a supplier could disrupt manufacturing. Within that, semiconductor chips are a pressure point: higher cost premiums on open-market chip purchases for its portable oxygen concentrators helped push 2025 gross margin down to 44.5%. On the revenue side, its rental business leans on Medicare, whose fee-for-service programs were about 61.9% of rental revenue in 2025, so changes to home-oxygen reimbursement rates or policy would directly hit that stream.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Sole-source dependency
- Single-source / limited suppliers for key components and completed productshigh
Inogen sources some components, subassemblies, and completed products from single-source suppliers or a limited group of manufacturers; some components are available only in limited supply, so loss of a supplier could disrupt manufacturing and product sales.
“We obtain some components, subassemblies, and completed products included in our products from single source suppliers or from a limited group of manufacturers or suppliers.”
SEC filing →As of 2026
Commodity & input dependence
- Semiconductor chip cost premiums for portable oxygen concentratorsmedium
Inogen's sales gross margin fell to 44.5% in 2025 partly due to higher cost premiums on open-market purchases of semiconductor chips used in its portable oxygen concentrators, exposing it to chip availability and pricing.
“higher cost premiums associated with open-market purchases of semiconductor chips used in our POCs”
Regulatory & policy
- Medicare reimbursement dependence for rental revenuemedium
Medicare's traditional fee-for-service reimbursement programs accounted for ~61.9% of Inogen's rental revenue in 2025, so changes to Medicare reimbursement rates or policies for home oxygen could reduce that revenue stream.
“Medicare's service reimbursement programs accounted for 61.9 %, 56.3 % and 67.7 % of rental revenue in 2025, 2024 and 2023 , respectively”
SEC filing →As of 2026
Supplier concentration
- Three major vendors supply ~40% of raw material purchasesmedium
Inogen purchases raw materials from a limited number of vendors, concentrated in three major vendors that accounted for 17.9%, 12.1%, and 10.5% of total raw material purchases in 2025, creating dependence on a few suppliers.
“the Company's three major vendors accounted for 17.9 %, 12.1 % and 10.5 %, respectively, of total raw material purchases.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
Foxconn (Hon Hai Precision)
“we produce our Inogen Rove 6 concentrators and perform related repair activities using a contract manufacturer, Foxconn, located in the Czech Republic to improve our ability to efficiently service our European customers.”
Cited →Yuwell (Jiangsu Yuwell Medical Equipment & Supply Co., Ltd.)
“Yuwell (Hong Kong) Holdings Limited has agreed to purchase 2,626,425 shares of the Company's common stock at a price per share of $10.36, for an aggregate purchase price of approximately $27.2 million.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch